Stelara

New Validation for Treat-to-Target Approach In UC From Phase 3 Data

For patients with ulcerative colitis, new evidence indicates that deeper response at induction of biologic therapy, ...

FEBRUARY 24, 2020

FDA Okays Stelara for UC

The FDA has approved the use of ustekinumab (Stelara, Janssen) for the treatment of moderate to severe ulcerative ...

OCTOBER 21, 2019

Ustekinumab Demonstrates Activity In Patients Unresponsive to Other Biologics

The monoclonal antibody ustekinumab appears to be as effective as induction therapy in patients with ulcerative ...

APRIL 17, 2019

Ustekinumab Produces Clinical Response In Tough-to-Treat Crohn’s

Ustekinumab (Stelara, Janssen Biotech) appears to be effective in the treatment of patients with severe ...

SEPTEMBER 12, 2018

Ustekinumab 'Likely to Work Well for Long Duration,' New Data Suggest

Patients with Crohn's disease who experience an initial response to ustekinumab are likely to maintain response ...

MAY 15, 2017

FDA Approves Stelara Treatment for Crohn's Disease

The FDA has approved the first biologic therapy for patients with moderate to severe Crohn’s disease who have ...

NOVEMBER 16, 2016

Two Pathway Inhibitors Show Promise in Crohn’s Disease

San Diego—For the treatment of patients with moderate to severe Crohn’s disease (CD), inhibitors of two ...

SEPTEMBER 22, 2016

Load more